Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

In silico cell for TB drug discovery

21.06.2007
A team of researchers from the University of Surrey have completed the first genome-scale model of the microbe that causes tuberculosis. The model may be a highly useful tool to identify new drug targets and design new vaccines.

Tuberculosis remains one of the biggest killers in the world today being responsible for nearly ten million cases and one and a half million deaths each year. New strains are emerging that are resistant to all current front-line anti-tuberculous drugs so new drugs are urgently needed. However, little is known about the metabolism of the TB bacillus and, because of its slow growth, experiments take a very long time.

The Surrey group hopes to speed up the drug discovery process by building an in silico model of the agent that causes TB: a virtual TB bacillus. This model was constructed using information from the entire genome sequence of the pathogen and uses mathematical equations to model the flow of nutrients through the cell. The model is extremely complex, handling 848 different biochemical reactions and 726 genes. The Surrey team showed that the model successfully simulates many of the peculiar properties of the TB bacillus and identifies the drug targets of known anti-tuberculous drugs. But unlike the biological organisms, the in silico TB bacillus grows in nanoseconds so experiments that would normally take months can be performed in minutes. The group hope that the in silico model may be used to identify new drug targets, particularly those capable of killing persistent bacilli.

The work is published in the high-profile journal Genome Biology and describes not only the model but, for the first time, makes an in silico model available to other researchers via an interactive website. Researchers will be able to perform experiments on the virtual TB bacillus from a beach in Bombay or a mountaintop in Malawi. It is hoped that the availability of this novel research tool will stimulate new approaches to control of this deadly pathogen.

Stuart Miller | alfa
Further information:
http://www.surrey.ac.uk
http://portal.surrey.ac.uk/portal/page?_pageid=799,1554681&_dad=portal&_schema=PORTAL

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>